Physical and functional interactions between STAT3 and Kaposi’s sarcoma-associated herpesvirus-encoded LANA  by Muromoto, Ryuta et al.
FEBS Letters 580 (2006) 93–98Physical and functional interactions between STAT3 and
Kaposis sarcoma-associated herpesvirus-encoded LANA
Ryuta Muromotoa,1, Kanako Okabea,1, Masahiro Fujimurob, Kenji Sugiyamac,
Hideyoshi Yokosawab, Tsukasa Seyad, Tadashi Matsudaa,*
a Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
b Department of Biochemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
c Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Research Institute, 3-10-1 Yato, Kawanishi, Hyogo 666-0193, Japan
d Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
Received 22 October 2005; revised 22 November 2005; accepted 23 November 2005
Available online 6 December 2005
Edited by Lukas HuberAbstract The Kaposi’s sarcoma-associated herpesvirus
(KSHV)-encoded latency-associated nuclear antigen (LANA)
is known to modulate viral and cellular gene expression. We
show that LANA directly associates with an interleukin-6 signal
transducer, signal transducer and activator of transcription 3
(STAT3) and that LANA enhances the transcriptional activity
of STAT3. Coimmunoprecipitation studies documented a physi-
cal interaction between LANA and STAT3 in transiently trans-
fected 293T cells as well as the KSHV-infected primary eﬀusion
lymphoma (PEL) cell line. Furthermore, small-interfering RNA-
mediated reduction of LANA expression decreased the STAT3-
dependent transcription in KSHV-positive PEL cells, whereas
overexpression of LANA enhanced STAT3 activity in KSHV-
negative B lymphoma cells. These data demonstrate that LANA
is a transcriptional co-activator of STAT3, and may have impli-
cations for the pathogenesis of KSHV-associated diseases.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Signal transducer and activator of transcription 3 (STAT3)
was originally cloned as an acute-phase response factor acti-
vated by interleukin-6 (IL-6) in mouse liver, and also by
homology to STAT1 [1,2]. Growth factors, such as epidermal
growth factor, platelet-derived growth factor and colony-stim-
ulating factor-1, can also stimulate STAT3 activity [1,2].
STAT3 is also known to play crucial roles in early embryonic
development as well as in other biological responses including
cell growth and apoptosis [1–3]. Furthermore, STAT3 is con-
stitutively activated in oncogene-transformed cells and variousAbbreviations: STAT, signal transducer and activator of transcription;
KSHV, Kaposi sarcoma-associated herpesvirus; LANA, latency-asso-
ciated nuclear antigen; PEL, primary eﬀusion lymphoma
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also known to be associated with STAT3 activation. STAT3
is constitutively activated in human T cell lymphotrophic virus
I-transformed T cells and Epstein–Barr virus (EBV)-related
lymphoma cell lines [5–7]. The herpesvirus saimiri tyrosine ki-
nase-interacting protein Tip-484 also activates STAT3 [8].
The Kaposis sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8, has been associated with
HIV-related and -unrelated cases of Kaposis sarcoma, pri-
mary eﬀusion lymphoma (PEL), and multicentric Castleman
disease [9–11]. The majority of KSHV-infected cells harbor
the virus in a latent form. During viral latency, latency-associ-
ated nuclear antigen (LANA), is critical to the persistence of
KSHV episomes and functions in this capacity by tethering
viral episomes to chromosomes during mitosis [12–14]. Viral
IL-6, the KSHV homolog of human IL-6, is known to serve
as an autocrine growth factor for KSHV-infected PEL cells
[15]. Furthermore, STAT3 plays a critical role in promoting
survival of KSHV-infected PEL cells [16]. LANA physically
interacts with cellular proteins, such as p53, pRB and GSK3b,
resulting in inhibition of p53-mediated apoptosis, dysregula-
tion of b-catenin and the Wnt signaling pathway [17–19].
In present study, we examined the physical and functional
interactions between STAT3 and LANA in a KSHV-infected
PEL cell line. Furthermore, RNA interference and overexpres-
sion experiments conﬁrmed that LANA modulates STAT3
activity in the KSHV-infected or -uninfected human B lym-
phoma cells. Thus, these data show that LANA is a transcrip-
tional co-activator of STAT3.2. Materials and methods
2.1. Reagents and antibodies
Recombinant human IL-6, interferon (IFN)-b and erythropoietin
(EPO) were kindly provided from Ajinomoto (Tokyo, Japan), Sumi-
tomo Pharmaceuticals (Osaka, Japan) and Kirin Company. (Tokyo,
Japan), respectively. Recombinant human LIF was purchased from
INTERGEN (Purchase, NY). Expression vectors, epitope-tagged
STAT3, STAT3YF, STAT3–LUC, STAT3-C, EPO receptor, ISRE–
LUC, STAT5–LUC were provided by Dr. T. Hirano (Osaka Univer-
sity, Osaka, Japan), Dr. J.F. Bromberg (Rockefeller University, New
York, NY), Dr. J.N. Ihle (St. Jude CRH, Memphis, TN) and Dr. D.
Wang (The Blood Res. Inst., Milwaukee, WI), respectively [20,21].
FLAG–LANA (pDY52) and LANA–SiRNAs (siN–LANA and siC–
LANA) cloned into pSuper plasmid were previously described [18].
FLAG–LANA deletion mutants were generated by PCR andblished by Elsevier B.V. All rights reserved.
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mAb was purchased from Advanced Biotechnologies Inc. (Maryland
USA). Anti-Myc, anti-GST, anti-STAT3, anti-cyclin D1 and anti-
cdk4 antibodies were purchased from Santa Cruz Biotechnology (San-
ta Cruz, CA). Anti-phosphoSTAT3 (Tyr705) was purchased from Cell
signaling Technologies (Beverly, MA). Anti-FLAG M2 mAb, rabbit
polyclonal anti-FLAG antibody were purchased from Sigma (St.
Louis, MO). Fluorescein isothiocyanate (FITC)-conjugated anti-rabbit
IgG, rhodamine-conjugated anti-mouse IgG, anti-Actin were pur-
chased from Chemicon (Temecula, CA).
2.2. Cell culture, transfections, and luciferase assays
Human embryonic kidney carcinoma cell line, 293T was maintained
in DMEM containing 10% fetal bovine serum (FBS) and transfected
by the standard calcium precipitation protocol. Luciferase (LUC) as-
say was performed as described [22]. Human hepatoma cell line Hep3B
was maintained in DMEM containing 10% FBS and transfected with
using jetPEI (PolyPlus-transfection, Strasbourg, France) according to
the manufacturers instructions [23]. Before stimulation, the cells were
cultured for 12 h in DMEM containing 1% FBS followed by treatment
with IL-6.
2.3. Nucreofection and reporter assay of B cells
HBL6 cells (KSHV+, EBV+) and DG75 cells (KSHV, EBV) were
grown in RPMI 1640 medium containing 10% FBS. 5 · 106 of HBL6
(or DG75) cells were nucreofected with 2.5 lg of STAT3–LUC,
0.3 lg of pRL-TK (for internal control) and 2.5 lg of LANA siRNA
plasmid (or FLAG–LANA) [19] by Human B Cell Nucleofector Kit
(Amaxa biosystems, Cologne, Germany). Cells were resuspended in
0.2 ml of lysis solution, passive lysis buﬀer (Promega, Madison, WI)
for LUC assay.
2.4. Immunoprecipitation, immunoblotting and indirect
immunoﬂuorescence
Immunoprecipitation, Western blotting and indirect immunoﬂuores-
cence were performed as described previously [24].3. Results and discussion
3.1. STAT3 and LANA physically interact in vivo
IL-6/STAT3 signaling has been documented to play crucial
roles in the development of the KSHV-associated diseases
[15,16]. These facts led us to examine the molecular interac-
tions between an IL-6 signaling molecule, STAT3 and a most
abundant latent protein, LANA in KSHV-infected cells. We
ﬁrst examined whether LANA physically interacts with
STAT3. To demonstrate in vivo binding of LANA to STAT3,
we performed coimmunoprecipitation studies in 293T cells
that were transiently transfected with FLAG–LANA and
Myc–STAT3 expression constructs. The transfected 293T
cells were lysed and subjected to immunoprecipitation with
anti-FLAG antibody. Immunoprecipitates were then used in
Western blot analysis with anti-Myc antibody. As shown in
Fig. 1A, STAT3 interacted with LANA in 293T cells. To
further establish the relevance of the interaction between
endogenous LANA and STAT3, we performed co-immuno-
precipitation studies on the KSHV-positive BC3 PEL cell line.
In KSHV-positive PEL cells but not negative B lymphoma
cells, STAT3 was constitutively tyrosine-phosphorylated
(data not shown). Immunoprecipitates with anti-STAT3, but
not control IgG, successfully pulled down LANA as demon-
strated by Western blotting with an anti-LANA antibody
(Fig. 1B). Similar immunoprecipitation studies on KSHV-
negative B lymphoma DG75 cells as well as immunoprecipita-
tion with an IgG control antibody, served as negative controls
(Fig. 1B).To next delineate the domains in the LANA that mediate the
protein–protein interactions between LANA and STAT3, co-
immunoprecipitation experiments were performed with a series
of mutant LANA proteins (Fig. 1C). As shown in Fig. 1D (left
panels), Deletion of LANA central repeat domain (LANA-
NC, D332–931) and the C-terminal domain of LANA
(LANA-C, 932–1162) interacted with STAT3, whereas the
N-terminal domain of LANA (LANA-N, 1–331) failed to
interact with STAT3. These data suggest that the C-terminal
domain is required for LANA to interact with STAT3.
To characterize further the nature of the interaction between
STAT3 and LANA, we attempted to determine where this
interaction occurs in cells. LANA localized in the nucleus in
the presence or absence of IL-6-stimulation, while IL-6 stimu-
lation induced translocation of STAT3 into nucleus in Hep3B
cells (Fig. 1E). The cytoplasmic STAT3 did not co-localize
with LANA. However, after IL-6 stimulation, STAT3 translo-
cated into nucleus and co-localized with LANA (Fig. 1D).
Consistent with the in vivo interaction data presented above,
these results suggest that the activated STAT3 interacts with
LANA in the nucleus.
3.2. LANA augments transcriptional activation of STAT3 in
293T cells
To assess the functional relevance between LANA and
STAT3, we tested whether LANA aﬀects STAT3-mediated
transcriptional activation using transient transfection experi-
ments in 293T cells. The STAT3-mediated transcriptional re-
sponses were measured by using STAT3–LUC, in which the
a2-macroglobulin promoter drives expression of the LUC re-
porter gene [20]. 293T cells were transfected with STAT3–
LUC together with or without LANA, and treated with LIF
and LUC activities were determined. When cells were co-
transfected with LANA, the transcriptional activation of
STAT3–LUC augmented in a dose-dependent manner
(Fig. 2A). Co-expression of a dominant negative STAT3, STA-
T3YF inhibited LANA-mediated augmentation of STAT3
activation, suggesting that LANA aﬀected the STAT3-medi-
ated transcriptional activity. To next assess the direct interac-
tion between STAT3 and LANA, we used a constitutively
active form of STAT3, STAT3–C [21]. 293T cells were trans-
fected with STAT3–LUC and expression vectors for LANA
and/or STAT3–C. As shown in Fig. 2B, STAT3–LUC activa-
tion by STAT3–C was augmented by LANA in a dose depen-
dent manner. We also tested whether LANA induces IL-6
mRNA in 293T cells by RT-PCR. However, any IL-6 mRNA
expression was observed after LANA expression in 293T cells
(data not shown). We next examined the eﬀects of LANA on
the IFN-b-induced STAT1 and EPO-induced STAT5 activa-
tion using similar transient transfection experiments. However,
LANA aﬀected neither STAT1 nor STAT5 activation (Fig. 2C
and D). These results indicate that LANA activates STAT3
transcriptional activity but not STAT1 and STAT5, suggesting
LANA acts on STAT3 in a speciﬁc manner. To further under-
stand the molecular mechanisms responsible for LANA-
mediated enhanced STAT3 activation, we examined whether
LANA expression aﬀects phopshorylation, dimerization,
nuclear translocation/retention or DNA binding activity of
STAT3, however, we could not observe any signiﬁcant eﬀect
on these issues by LANA expression in 293T cells (data not
shown). We also examined whether LANA physically interacts
with unphosphorylated STAT3, such as STAT3YF. In 293T
Fig. 1. STAT3 and LANA physically interact in vivo. (A) 293T cells (1 · 107 cells) were transfected with FLAG–LANA (20 lg) together with or
without Myc–STAT3 (10 lg). Forty-eight hours after transfection, the cells were lysed, and immunoprecipitated with anti-FLAG antibody and
immunoblotted with anti-Myc (upper panel) or anti-LANA antibody (middle panel). Total cell lysates (1%) were blotted with anti-Myc or anti-
LANA antibody (lower panels). (B) Human Burkitts lymphoma DG75 (KSHV-negative) or primary eﬀusion lymphoma (PEL) BC3 (KSHV-
positive) cells (2 · 107) were lysed, and immunoprecipitated with control IgG or anti-STAT3 antibody and immunoblotted with anti-LANA antibody
(upper panels) or anti-STAT3 antibody (lower panels). (C) Domain structure of LANA and mutant fragments are schematically shown. (D) 293T
cells (1 · 107 cells) were transfected with Myc–STAT3 (10 lg) together with or without LANA-N (1–331), LANA-C (932–1162) and LANA-NC
(D332–931) (10 lg). Forty-eight hours after transfection, the cells were lysed, immunoprecipitated with anti-Myc antibody and immunoblotted with
anti-FLAG or anti-Myc antibody (left panels). Total cell lysates (1%) were blotted with anti-FLAG or anti-Myc antibody (right panels) to monitor
the expression of LANA or STAT3 proteins. The asterisks indicate the migration position of LANA mutants. (E) Hep3B cells were transfected with
Myc–STAT3 (1 lg) and FLAG–LANA (1 lg). Thirty hours after transfection, cells were treated with or without IL-6 (100 ng/ml) for 40 min, and
then ﬁxed and reacted with rabbit anti-FLAG polyclonal and mouse anti-Myc monoclonal antibody and visualized with FITC-conjugated anti-
rabbit antibody or rhodamine-conjugated anti-mouse IgG antibody.
R. Muromoto et al. / FEBS Letters 580 (2006) 93–98 95cells, we could detect a direct interaction between LANA and
STAT3YF (data not shown), suggesting that phosphorylation
of STAT3 may be not necessary for their physical interactions.However, LANA-mediated enhanced STAT3 activation was
observed only after LIF stimulation. These results indicate
that STAT3 can interact with LANA in the nucleus after its
Fig. 2. LANA augments transcriptional activation of STAT3 in 293T cells. (A) 293T cells in a 12-well plate were transfected with STAT3–LUC
(0.2 lg) and/or indicated amounts of empty vector, expression vector for LANA or STAT3YF. Thirty-six hours after transfection, the cells were
stimulated with LIF (100 ng/ml) for additional 12 h. The stimulated cells were harvested, and LUC activities were measured. (B) 293T cells in a 12-
well plate were transfected with STAT3–LUC (0.2 lg) together with or without STAT3-C (500 ng) and/or indicated amounts (100–400 ng) of
expression vector for LANA. Forty eight hours after transfection, the cells were harvested, and LUC activities were measured. (C) 293T cells in a 12-
well plate were transfected with ISRE–LUC (0.4 lg) and/or indicated amounts (100–400 ng) of expression vector for LANA. Thirty-six hours after
transfection, the cells were stimulated with IFN-b (50 U/ml) for additional 8 h. The stimulated cells were harvested, and LUC activities were
measured. (D) 293T cells in a 12-well plate were transfected with STAT5–LUC (0.4 lg) together with EPO receptor (0.05 lg) and/or indicated
amounts (100–400 ng) of expression vector for LANA. Thirty-six hours after transfection, the cells were stimulated with EPO (0.03 U/ml) for
additional 12 h. The stimulated cells were harvested, and LUC activities were measured. The above results are indicated as fold induction of LUC
activity from triplicate experiments, and the error bars represent the S.D.
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be required to clarify the molecular mechanisms of LANA-
mediated enhancement of STAT3 activation.
3.3. LANA acts as a transcriptional activator for STAT3 in B
cells
To understand the physiology of molecular interactions be-
tween STAT3 and LANA, we further examined the eﬀects of
LANA gene silencing on STAT3 activity in KSHV-infected
PEL cells. We co-transfected STAT3–LUC construct with the
LANA or control siRNA into HBL6 cells and assessed reporter
gene expression. LANA siRNA reduced expression of cellular
LANA expression by about 50% compared to control siRNA
(Fig. 3A). Importantly, the LANA siRNA markedly reduced
the STAT3 target gene expression, such as cyclin D1 and cdk4
[21] as well as the reporter gene expression from the STAT3–
LUC construct compared to the control siRNA, although the
phosphorylation level of STAT3 did not alter by treatment of
LANA siRNA (Fig. 3A). To further conﬁrm the enhanced eﬀect
of LANA on STAT3 activation, we overexpressed LANA to-gether with the STAT3–LUC construct in a KSHV-negative
DG75 cells. As shown in Fig. 3B, ectopically expressed LANA
markedly augmented STAT3–LUC in DG75 cells. These data
indicate that LANA plays a critical role in the enhanced STAT3
activation in KSHV-infected PEL cells.
3.4. Concluding remarks
STAT3 is constitutively phosphorylated and activated in
various primary human tumors and in transformed cell lines
and is implicated in tumorigenesis [2–4]. However, molecular
mechanisms of the persistent activation of STAT3 in human
tumor cells are largely unknown. Recently, the hepatitis C
virus (HCV) core protein has been shown to directly interact
with and activate STAT3 through phosphorylation of the crit-
ical tyrosine residue [25]. Chronic infection by HCV is known
to associate with development of liver cirrhosis and hepatocel-
lular carcinoma. HCV core protein is also proposed to be in-
volved in the virus-induced transformation, indicating that
the HCV core protein cooperates with STAT3, which leads
to cellular transformation.
Fig. 3. LANA acts as a transcriptional activator for STAT3 in B cells. (A) To abolish expression of endogenous LANA and measure LUC activities
from STAT3 signaling, HBL6 cells were nucreofected with 2.5 lg of LUC reporter (STAT3–LUC), 0.3 lg of pRL-TK and and 2.5 lg of LANA
siRNA expressing plasmid (1.25 lg of siN–LANA and 1.25 lg of siC–LANA) or 2.5 lg of control siRNA plasmid by nucreofection with Human B
Cell Nucleofector Kit according to their optimized protocol. Cells were harvested after 2 (Exp. #2) and 3 days (Exp. #1) and resuspended in 0.2 ml of
lysis solution for LUC assay. One part of lysate was subjected to Western blotting analysis using anti-LANA rat mAb to conﬁrm the knock down of
LANA expression. The same samples were also subjected to Western blotting analysis using anti-phosphoSTAT3 (Tyr705), anti-STAT3, anti-cyclin
D1 or anti-cdk4 antibodies. (B) DG75 cells were nucreofected with 2.5 lg of STAT3–LUC, 0.3 lg of pRL-TK and 2.5 lg of FLAG–LANA by
nucleofector as well as HBL6 and cells were harvested after 5 (Exp. #1) and 6 days (Exp. #2). Nucreofection was done with a total of 5 lg of DNA
(adjusted with vector plasmid as a carrier) per each sample. Cells lysate were subjected to LUC assay and Western blotting with anti-LANA rat mAb.
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STAT3 and the KSHV-derived LANA in PEL cells. LANA
augmented transcriptional activity of STAT3 in 293T cells.
Furthermore, small-interfering RNA-mediated reduction of
LANA expression decreased the STAT3-dependent transcrip-
tion in KSHV-positive PEL cells, whereas overexpression of
LANA enhanced STAT3 activity in KSHV-negative B cells.
Thus, further understanding of the detailed molecular interac-
tions between STAT3 and LANA may provide a novel thera-
peutic strategy for the KSHV-associated tumors.
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